Events
4th QLD mRNA Symposium
On International RNA Day (1 August), the BASE facility hosted the 4th QLD mRNA Symposium, bringing together leading experts from research, clinical, government, and industry to discuss advances in mRNA medicines.
News
Stay informed with the latest developments in mRNA science and manufacturing. Find updates on mRNA technology advancements, regulatory milestones, industry trends, and company announcements.
News
mRNA-LNP masterclass
Our graduates successfully completed the first Winter mRNA Masterclass, a week-long intensive program that trains students in the science, computational design, and laboratory production of mRNAs and LNPs.
News
Our workflow published
We published our step-by-step protocol for mRNA-LNP production, describing the design, manufacture, and quality control of mRNA medicines using standard equipment in a research laboratory.
News
BASE receives BARDA Patch Forward prize
In partnership with Vaxxas, BASE scientists were awarded the BARDA Patch Forward Prize to develop mRNA vaccines delivered using high-density microarray patches (HD-MAPs).
News
Our design software for mRNA medicines
BASE scientists released mRNArchitect, a software platform for designing mRNA medicines. The software enables users to optimise mRNA sequences for improved translation efficiency, stability, and immunogenicity, and has been experimentally validated across a wide range of applications.
News
Targeting LNPs for cell-specific delivery of mRNA
The targeted delivery of mRNA therapeutics remains a major challenge in treating disease. BASE scientists have published a method in Molecular Therapy – Nucleic Acids that directs mRNA–LNPs to specific cells and tissues using bispecific antibodies that bind mRNA–LNPs to cell-surface receptors.
News
BASE partners with Oxford Nanopore Technologies
BASE has partnered with Oxford Nanopore Technologies to develop nanopore sequencing methods for analysing mRNA during manufacture. These technologies enable measurement of mRNA sequence, integrity, and purity to support improved quality control.
News
MRFF funding for personalised mRNA cancer vaccines
BASE scientists have been awarded funding from the Medical Research Future Fund (MRFF) to provide cancer researchers with access to personalised mRNA vaccine technologies. This funding will enable researchers to design mRNA cancer vaccines tailored to individual patients.
News
BASE receives ARC funding to improve mRNA quality control
In partnership with Oxford Nanopore Technologies, BASE has been awarded funding from the Australian Research Council (ARC) to routinely integrate nanopore sequencing into mRNA manufacturing processes.
News
MRFF and Sanofi support BASE mRNA facility
BASE has received funding from the Medical Research Future Fund (MRFF) and Sanofi to establish a national mRNA–LNP production facility supporting translational research by Australian scientists.
Enquiries
Our team is available to help with your mRNA projects.